A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication
Explore this paper's citation graph
Summary
KP appears to be the first antibody-derived short peptide displaying an inhibitory activity against HIV-1 and related opportunistic micro-organisms by different mechanisms of action.
- Type
- article
- Published
- 2006-04-01
- Cited by
- 22
- References
- 33
- OpenAlex
- https://openalex.org/W16603848
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:27931087
Keywords
Political science, Welfare economics, Economics
References
- Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'- dideoxynucleosides
- Inhibitory Effect of Human Natural Yeast Killer Toxin-like Candidacidal Antibodies on Pneumocystis carinii
- HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1alpha.
- Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria
- “In vitro” Antifungal activity of protease inhibitors
- Defensins: natural anti-HIV peptides.
- Involvement of β-Glucans in the Wide-Spectrum Antimicrobial Activity of Williopsis saturnus var. mrakii MUCL 41968 Killer Toxin
- Human natural yeast killer toxin-like candidacidal antibodies.
- Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop
- A synthetic peptide as a novel anticryptococcal agent
- Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy.
- Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems.
- Minidefensins: antimicrobial peptides with activity against HIV-1.
- Opportunistic Infections in the Age of Highly Active Antiretroviral Therapy
- [Fungal infections in HIV-infected patients].
- Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity
- Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection.
- The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection
- Therapeutic Activity of an Engineered Synthetic Killer Antiidiotypic Antibody Fragment against Experimental Mucosal and Systemic Candidiasis
- Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
Cited by
- Phenotypic modulation of porcine CD14+ monocytes, natural killer/natural killer T cells and CD8αβ+ T cell subsets by an antibody-derived killer peptide (KP).
- Quel avenir pour des thérapeutiques anti-infectieuses non antibiotiques ?
- Antibody Complementarity-Determining Regions (CDRs): A Bridge between Adaptive and Innate Immunity
- Antibody Constant Region Peptides Can Display Immunomodulatory Activity through Activation of the Dectin-1 Signalling Pathway
- Antibodies as an Unlimited Source of Anti-Infective, Anti-Tumour and Immunomodulatory Peptides
- β-Actin-binding Complementarity-determining Region 2 of Variable Heavy Chain from Monoclonal Antibody C7 Induces Apoptosis in Several Human Tumor Cells and Is Protective against Metastatic Melanoma*
- Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities
- Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders
- From yeast killer toxins to antibiobodies and beyond.
- From Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy
- Antibodies as a source of anti-infective peptides: an update.
- Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs.
- Peptides from the inside of the antibodies are active against infectious agents and tumours
- Therapeutic Activity of an Anti-Idiotypic Antibody-Derived Killer Peptide against Influenza A Virus Experimental Infection
- Screening of a Saccharomyces cerevisiae nonessential gene deletion collection for altered susceptibility to a killer peptide.
- In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs.
- Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins
- An engineered anti-idiotypic antibody-derived killer peptide (KP) early activates swine inflammatory monocytes, CD3+CD16+ natural killer T cells and CD4+CD8α+ double positive CD8β+ cytotoxic T lymphocytes associated with TNF-α and IFN-γ secretion.
- From antimicrobial to anticancer: the pioneering works of Prof. Luiz Rodolpho Travassos on bioactive peptides
- Bioactive peptides: an alternative therapeutic approach for cancer management
Related papers
No related papers recorded.